Flexibility using single-use System
Business Overview
SK bioscience has established a broad product portfolio and continues to invest in vaccine research,
which will be the driving force in the life science business going forward.
We will develop premium vaccines based on state-of-the-art technology and contribute to the promotion of public health.
which will be the driving force in the life science business going forward.
We will develop premium vaccines based on state-of-the-art technology and contribute to the promotion of public health.
Speed of Execution with Quality
SKYVAX Program
SK’s proprietary product supply to
developing countries including LMIC
Platform Technology
- - Contractual development & manufacturing service
- - Technology transfer to local manufacture including JV model
Manufacturing Versatility
Out-licensing or co-development
for US and Europe market for next decade
Market Leading Sales
/ Marketing Infrastructure
/ Marketing Infrastructure
- Joint sales and consignment production
based on leading position
in domestic vaccine market
Share Innovation
Key milestones of SK bioscience
-
2009
- Out-licensed CSL’s NBP601 (hemophilia drug), Korea’s first bio-pharmaceutical drug
-
2013
- Established partnership with IVI (International Vaccine Institute)
to collaborate on the development of a new typhoid conjugate vaccine
- Established partnership with IVI (International Vaccine Institute)
-
2014
- Established strategic partnership with Sanofi Pasteur for co-development of next-generation pneumococcal conjugate vaccine
-
2015
- Launched SKYCellflu, Korea’s first trivalent cell culture-derived influenza vaccine
-
2016
- Launched SKYCellflu Quadrivalent, world’s first quadrivalent cell culture-derived influenza vaccine
- Gained approval for SKYPneumo, the first domestically produced PCV13 vaccine
-
2017
- Launched Sky Zoster Inj.,
world’s second shingles vaccine - Signed agreement with international organization PATH to develop and produce pediatric enteritis vaccine
for developing countries
- Launched Sky Zoster Inj.,
-
2018
- SKY Varicella Inj. licensed to market, Korea’s second chickenpox vaccine
- Signed an agreement with Sanofi Pasteur to license out cell-culture technology for producing cell culture-derived influenza vaccines
-
2019
- Gained WHO PQ for SKY Cellflu prefilled syringe/ SKY Cellflu Quadrivalent prefilled syringe (world’s first for cell-cultured influenza vaccine)
- Gained WHO PQ for SKY Varicella Inj.
as world’s second
-
2020
- Announced as WAVE2 by CEPI with GBP510 (COVID-19 vaccine)
- Started clinical trial for in-house produced COVID-19 vaccine (GBP510, NBP2001)
- Started phase 2 clinical trial for the next-generation pneumococcal conjugate vaccine co-developed with Sanofi Pasteur
- Signed CMO agreement with AstraZeneca for the consigned production of COVID-19 vaccine
- Signed CDMO agreement with Novavax for COVID-19 vaccine
-
2021
- Started phase 3 trial for COVID-19 vaccine candidate 'GBP510'
- Funded to develop a vaccine candidate against COVID-19 (SARS-CoV-2) variants (CEPI)
- Submitted application for export permit of typhoid vaccine co-developed with IVI
- Signed licensing & purchase agreement for Novavax’s COVID-19 vaccine candidate (Novavax, KDCA)
- Obtain EU-GMP Certification for COVID-19 Vaccine Facilities
-
2022
- Publish first TCFD report
- Receive 'Grade A' rating on ESG Evaluation from the Korea Institute of Corporate Governance & Sustainability
- Donate to international Vaccine Institute to support global vaccine R&D
- Signed Advance Purchase Agreement of GBP510(KDCA)
- Agreed SKYvaricella distribution(PAHO)
- Achieved Turkish GMP Certification (TITCK)
- Achieved BLA of SKYTyphoid for export
- Published first ESG report
- Achieved BLA of SKYCovione (KMFDS)
-
2023
- Achieve ISO 27001 Certification
- Receive approval of world-first cell culture based quadrivalent influenza vaccine in Chile
- Receive biologics license application approval of zoster vaccine in malaysia
Business field
Process development
Bio R&D center
- Various platform technologies for diverse vaccine types
- Process development team
- Evaluation/analysis team
- Bacterial vaccine team
- Viral vaccine team
- New project team
Development & commercial manufacturing
L House
- Pioneer in successful adaptation of ‘single-use system’ for vaccines on commercial scale
- ‘Multi-modular system’ for diverse vaccine types
-
-
Diverse platforms
-
Future expansion
Professional sales/marketing
Professional
- Specialized sales/marketing infrastructure make company the leader in the domestic vaccine market
- Various consignment production systems increase the convenience of vaccination
-
Unified system from licensing to selling
-
Specialized strategies for public/private market
-
Portfolio for all ages,
from infants to elderly